LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on LifeStance Health Group, with six buy ratings, one strong-buy rating and four holds. The average 12-month price target is $12.13.
• LifeStance exceeded quarterly expectations, reporting EPS of $0.06 versus $0.03 expected and revenue of $435.35 million, up 26.1% year over year.
• Shares opened at $12.42, near the one-year high of $12.76, while insiders sold approximately $155 million of stock over the past 90 days; institutional investors own 85.5% of the company.

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $12.1250.

Several research firms have weighed in on LFST. Wall Street Zen upgraded shares of LifeStance Health Group from a "buy" rating to a "strong-buy" rating in a report on Saturday. Zacks Research lowered shares of LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. BTIG Research upped their price objective on shares of LifeStance Health Group from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Friday, August 7th. KeyCorp raised their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an "overweight" rating in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. lifted their target price on LifeStance Health Group from $9.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday.

LifeStance Health Group Stock Performance

Shares of LFST stock opened at $12.42 on Friday. The stock has a market cap of $4.82 billion, a PE ratio of 95.55 and a beta of 1.14. The stock has a 50-day moving average of $10.39 and a 200-day moving average of $8.22. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. LifeStance Health Group has a one year low of $4.77 and a one year high of $12.76.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The business had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. LifeStance Health Group's quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.01) EPS. As a group, sell-side analysts expect that LifeStance Health Group will post 0.15 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Lisa K. Miller sold 47,912 shares of LifeStance Health Group stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the transaction, the chief operating officer owned 281,289 shares in the company, valued at $3,051,985.65. The trade was a 14.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the transaction, the insider owned 98,101,407 shares of the company's stock, valued at $1,041,836,942.34. This represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 14,629,850 shares of company stock valued at $154,952,012 over the last ninety days. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of LFST. Assetmark Inc. boosted its holdings in shares of LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company's stock valued at $60,000 after buying an additional 1,367 shares during the period. California State Teachers Retirement System raised its holdings in shares of LifeStance Health Group by 1.6% during the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company's stock worth $885,000 after acquiring an additional 1,966 shares during the period. Vident Advisory LLC raised its holdings in shares of LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company's stock worth $112,000 after acquiring an additional 2,447 shares during the period. Xponance LLC raised its holdings in shares of LifeStance Health Group by 26.4% during the fourth quarter. Xponance LLC now owns 13,144 shares of the company's stock worth $93,000 after acquiring an additional 2,745 shares during the period. Finally, Diversified Trust Co lifted its position in LifeStance Health Group by 14.8% in the 1st quarter. Diversified Trust Co now owns 21,532 shares of the company's stock valued at $137,000 after acquiring an additional 2,770 shares in the last quarter. Institutional investors own 85.50% of the company's stock.

LifeStance Health Group Company Profile

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source